Carmine Therapeutics picks CEO
Carmine Therapeutics Inc., an emerging leader in gene therapy, appointed Don Haut, Ph.D. as CEO and member of the board of directors.
“We are thrilled to welcome Don to the Carmine team,” says XQ Lin, founder/chairman of Carmine. “Carmine has made tremendous progress in advancing the research and development of our platforms, and is now moving an extensive pipeline into the clinic. Don’s deep industry expertise and vast experience across multiple biotech companies will accelerate Carmine’s growth and transformation as it continues to advance a new generation of gene therapies.”
Dr. Haut brings more than two decades of healthcare experience to Carmine, most recently as chief business officer of AskBio where he was instrumental in AskBio’s recent $4 billion acquisition by Bayer AG, according to company executives.
He was previously chief business officer of Sherlock Biosciences and Histogenics Inc. Prior to that, Dr. Haut was VP for new business ventures and VP for U.S. sales operations at The Medicines Company, Inc. In addition, he held senior leadership roles at Smith & Nephew Plc. and 3M Company. He started his career at Monsanto and McKinsey & Company.
Dr. Haut currently serves on the board of directors at Xiros Ltd., and the partnering advisory board of Antibe Therapeutics. He earned an MBA at the Olin School of Business at Washington University in St. Louis, and a Ph.D. in molecular microbiology and immunology at the School of Medicine at the University of Missouri-Columbia, and his undergraduate degree at the College of Wooster.
According to Dr. Haut, Carmine’s REGENT technology platform “has the potential to be truly transformational in multiple therapeutic areas and indications. The founders have done a remarkable job building the company to where it is today, and I am thrilled to be joining such a thoughtful and talented group.”